Harold Keer
Corporate Officer/Principal bei Stanford University
Profil
Harold Keer is a Clinical Faculty Member at Stanford University.
He previously worked as a Principal at Titan Pharmaceuticals, Inc., Vice President-Clinical Development at Exelixis, Inc., and Vice President-Clinical Development at Five Prime Therapeutics, Inc. Keer earned a doctorate degree from Northwestern University.
Aktive Positionen von Harold Keer
| Unternehmen | Position | Beginn |
|---|---|---|
| Stanford University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Harold Keer
| Unternehmen | Position | Ende |
|---|---|---|
| EXELIXIS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| TITAN PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| FIVE PRIME THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Harold Keer
| Northwestern University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
